Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...
This represented 440,749 individuals who met Kidney Disease Improving Global Outcomes (KDIGO) clinical CKD criteria, ...